A Pilot Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ Relative to INBRIJA®

Sponsor

PureIMS B.V. (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT06037590

Collaborator

Cooperative Clinical Drug Research and Development AG (CCDRD AG) (Other)

Enrollment

Location

Arms

Anticipated Duration (Days)

37.7

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This unmet medical need was addressed by the approval of INBRIJA®, an orally inhaled product, for producing therapeutic relief during the OFF episodes. INBRIJA® is a capsule-based inhaler system and in order to administer the full dose of levodopa, the patients need to inhale the contents of two capsules. In order to administer the full dose of levodopa, patients need to inhale the contents of two capsules. Since the INBRIJA® device is a standalone and reusable unit, the patients have to load the capsule prior to inhalation several times a day during the OFF episodes (except early-morning OFF) to get relief. Also, the INBRIJA® device is repeatedly used by PD patients and therefore needs to be properly cleaned to avoid contamination.

PureIMS is developing a more user-friendly alternative called Levodopa Cyclops™, a pre-filled drug-device combination of levodopa inhalation powder for use with the Cyclops™ dry powder inhaler. Due to the nature of the Cyclops™, it offers PD patients greater ease and convenience in use. Moreover, the device's moderate to high resistance to airflow and minimal use of excipients suggests minimal cough episodes during oral inhalation.

The current study is planned in order to determine the dose at which comparative bioavailability of Levodopa Cyclops™ will be reached compared to INBRIJA®.

Condition or Disease	Intervention/Treatment	Phase
Parkinson Parkinson Disease Parkinson's Disease and Parkinsonism	Combination Product: Levodopa Cyclops™ Combination Product: INBRIJA®	Phase 1

Detailed Description

Patients with Parkinson's disease (PD) are commonly treated with a combination of levodopa and a decarboxylase inhibitor (DCI). However, many PD patients experience motor fluctuations (OFF episodes), even with their regular levodopa/DCI treatment. This unmet medical need was addressed by the approval of INBRIJA®, an orally inhaled product, which releases levodopa in the systemic circulation for producing therapeutic relief during the OFF episodes.

The INBRIJA® inhaler system is based on a spray-dried powder and contains 90% of levodopa, 8% dipalmitoyl phosphatidylcholine, and 2% sodium chloride. In order to administer the full dose of levodopa, patients need to inhale the contents of two capsules. Since the INBRIJA® device is a standalone and reusable unit, the patients have to load the capsule prior to inhalation several times a day during the OFF episodes (except early-morning OFF) to get relief. Also, the INBRIJA® device is repeatedly used by PD patients and therefore needs to be properly cleaned to avoid contamination.

PureIMS is developing a drug-device combination product called Levodopa Cyclops™, a pre-filled drug-device combination of levodopa inhalation powder for use with the Cyclops™ dry powder inhaler. The ready-to-use Cyclops™ carries a high load of drug (i.e., 98% levodopa with only 2% L-leucine serving as the excipient). Due to the nature of the Cyclops™, it offers PD patients greater ease and convenience in use. Moreover, the device's moderate to high resistance to airflow and minimal use of excipients suggests minimal cough episodes during oral inhalation.

Levodopa Cyclops™ has shown safety and tolerability in PD patients with no reports of cough episodes. The pharmacokinetics (PK) at 30, 60 and 90 mg Levodopa Cyclops™ doses show a dose proportional increase of exposure (Cmax and AUC) with a rapid attainment of Cmax (within 10 minutes after oral inhalation using Levodopa Cyclops™).

PureIMS plans to pursue drug development in the US via the 505(b)(2) regulatory pathway, referencing the safety and efficacy findings of the FDA for the approved levodopa inhaler INBRIJA®.

The current study is planned in order to determine the dose at which comparable relative bioavailability of Levodopa Cyclops™ will be reached compared to INBRIJA®. The selected Levodopa Cyclops™ dose will then be investigated against INBRIJA® in a formal comparative bioavailability study, in order to provide a PK bridge of Levodopa Cyclops™ to the reference listed drug.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

26 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Intervention Model Description:

Open-label, randomized, crossover, comparative bioavailability study in healthy volunteersOpen-label, randomized, crossover, comparative bioavailability study in healthy volunteers

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Pilot Open-label, Randomized, Crossover, Comparative Bioavailability Study of Levodopa Administered Via Levodopa Cyclops™ (Test Product) Relative to INBRIJA® (Reference Product) in Healthy Adult Subjects

Anticipated Study Start Date :

Sep 18, 2023

Anticipated Primary Completion Date :

Oct 9, 2023

Anticipated Study Completion Date :

Oct 9, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Test 1 - Levodopa Cyclops™ 45 mg 1 pre-filled single-use Levodopa Cyclops™ (= 45 mg levodopa)	Combination Product: Levodopa Cyclops™ Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
Experimental: Test 2 - Levodopa Cyclops™ 90 mg 2 pre-filled single-use Levodopa Cyclops™ devices (= 90 mg levodopa)	Combination Product: Levodopa Cyclops™ Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
Experimental: Test 3 - Levodopa Cyclops™ 135 mg 3 pre-filled single-use Levodopa Cyclops™ devices (= 135 mg levodopa)	Combination Product: Levodopa Cyclops™ Orally inhaled dry powder levodopa from the Cyclops™ dry powder inhaler
Active Comparator: Reference - Inbrija® 84 mg 2 Inbrija® capsules (42 mg levodopa per capsule) from the Arcus® dry powder inhaler	Combination Product: INBRIJA® Orally inhaled dry powder levodopa from the ARCUS® dry powder inhaler

Outcome Measures

Primary Outcome Measures

The dose at which comparative bioavailability of levodopa will be reached between Levodopa Cyclops™ versus Inbrija® [5 days]
The primary objective of the present trial is to determine the dose at which comparative bioavailability of levodopa will be reached between Levodopa Cyclops™ versus Inbrija® in healthy adult subjects after an oral inhalation of a single dose of 45, 90 and 135 mg levodopa under fasting conditions administered with 50 mg carbidopa one hour prior IMP administration in 3 study periods and after a single dose of 66 mg levodopa delivered dose (2 hard capsules containing 42 mg levodopa each) of Inbrija® administered with carbidopa 50 mg one hour prior to IMP administration in a fourth study period.

Secondary Outcome Measures

The time to reach a levodopa plasma concentration above 400 ng/mL as a measure for the onset of action. [5 days]
In the scientific literature it is stated that levodopa is effective at plasma concentrations above 400 ng/mL, therefore, the time it takes to reach this concentration with Levodopa Cyclops™ and Inbrija® is of interest and is indicative for the onset of action.
The time above a levodopa plasma concentration 400 ng/mL as a measure for the duration of effect. [5 days]
In the scientific literature it is stated that levodopa is effective at plasma concentrations above 400 ng/mL, therefore, the time above this concentration after a Levodopa Cyclops™ dose or Inbrija® dose is of interest.
Safety and tolerability of Levodopa Cyclops™ by measuring vital signs, laboratory examination and adverse events questioning [5 days]
Before and after the study: Vital signs (body temperature, pulse rate, respiratory rate, blood pressure) 12-lead ECG Laboratory examination blood and urine (Hematology, Chemistry, Serology, Serum FSH in females, Urinalysis) After each dose: Adverse event questioning Vital signs (pulse rate and blood pressure) measurement at 50 minutes post-dose

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 55 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Male or female subject
Age between 18 and 55 years (inclusive the date of signing informed consent)
Female subject who IS NOT of reproductive potential. A female subject who is NOT of reproductive potential is defined as one who:

(i) has reached natural menopause (defined as at least 6 months of spontaneous amenorrhea with serum follicle-stimulating hormone [FSH] levels in the postmenopausal range as determined by the local laboratory, or 12 months of spontaneous amenorrhea); (ii) is 6 weeks post-surgical bilateral oophorectomy with or without hysterectomy; or (iii) has undergone bilateral tubal ligation. Spontaneous amenorrhea does not include cases for which there is an underlying disease that causes amenorrhea (e.g. anorexia nervosa)

Female subject who IS of reproductive potential and uses reliable contraception method and/or is willing to use adequate birth control methods starting from the time of consent through 30 days after the last dose of study therapy

List of medically accepted contraceptive methods (used at least 4 weeks prior screening visit and not to be changed for the duration of the study):

Combination of a barrier method and spermicides (film, jelly, foam): e.g. female/ male condoms with spermicides, as well as diaphragm/ cervical cap/ contraceptive sponge with spermicides.
Hormonal methods: combined estrogen/progestin injectable and oral contraceptives; progestin injectable and oral contraceptives; implants (Nexplanon®), vaginal ring (NuvaRing®), skin patch (Xulane®) and contraceptive injection (Depo-Provera®).
Intrauterine devices (IUD): inert or copper IUD (ParaGard®), hormonal IUD (Mirena®, Skyla®, Kyleena®).

Physically and mentally healthy as judged by means of medical and standard laboratory examination
Non-smokers or ex-smokers (stopped at least 6 months ago) with a smoking history of ≤5 pack-year equivalents (1 pack-year equivalent is equal to smoking 1 pack per day for 1 year) and non-users of othernicotine containing products, confirmed by urine cotinine test
BMI within the range (including the borders) of 18.0 to 30.0 kg/m2
Normal spirometry values at screening (forced expiratory volume in one second [FEV1] and forced vital capacity [FVC] between 80% and 120% of the average value regarding age, height, gender and ethnicity (acc. to ECCS/ERS)1
Informed consent given in written form according to chapter 5.4 of clinical trial protocol

Exclusion Criteria:

Participation in another clinical trial at same time or within 90 days before screening visit (calculated from the date of the final examination of the previous study)
Randomization into the present trial more than once
Pregnant and/or nursing women. Positive pregnancy test
Weight of less than 40 kg
Blood donation or blood loss including plasmapheresis of >500 mL within 90 days before screening visit
History of drug abuse or use of illegal drugs: use of soft drugs, e.g. marihuana within 6 months before screening visit or hard drugs, e.g. cocaine, amphetamines, phencyclidine within 1 year before screening visit
Alcohol abuse, i.e. regular use of more than 2 units of alcohol per day or 10 units per week or a history of alcoholism (one unit of alcohol equals 250 mL beer, 125 mL wine or 25 mL spirits) or recovered alcoholics
Regular consumption of beverages or food containing methylxanthines (e.g. coffee, tea, cola, caffeine containing sodas, chocolate) equivalent to more than 500 mg methylxanthines per day
Positive drug screening
Positive alcohol test
History of significant multiple and/or severe allergies (including latex allergy, asthma or bronchial hyperreactivity), or has had an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food
Any history of drug hypersensitivity (especially to the active ingredient levodopa of the Test and Reference IMPs and to the active ingredient carbidopa of the AxMP) or intolerance to any sugar (e.g. fructose, glucose, or lactose)
Presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, hematological, gastrointestinal, neurological, psychiatric or other diseases
Clinically significant illness within 4 weeks before screening visit
Major surgery of the gastrointestinal tract except for appendectomy
Any chronic disease which might interfere with resorption, distribution, metabolism or excretion of the drug
History of difficulty in swallowing
Positive serologic findings for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), and/or hepatitis C virus (HCV) antibodies
Administration of depot injectable solutions or medications with a halflife >1 week (including study medications) within 6 months before screening visit
Intake of enzyme-inducing, organotoxic or long half-life drugs within 4 weeks before screening visit
Intake or administration of any systemic or topical medication (including OTC medication and especially intake of antacids e.g. aluminum hydroxide, magnesium hydroxide, and simethicone or herbal medication e.g. St. John's wort, kava kava) within 2 weeks before screening visit
Medication with drugs known to alter the major organs or systems such as barbiturates, phenothiazines, cimetidine, omeprazole etc. within 60 days before screening visit
Systolic blood pressure outside the range of 100 to 135 mmHg and/or diastolic blood pressure outside the range of 60 to 90 mmHg
Pulse rate outside the range of 50 to 90 beats/min
Respiratory rate outside the range of 12-16 breaths/min
Axillary body temperature outside the interval of 35.5 to 37.1°C
Any clinically significant abnormality of the resting ECG (12-lead)
Laboratory values outside normal range with clinical relevance
Special diet due to any reason, e.g. vegetarians
Subjects who are known or suspected:

not to comply with the study directives
not to be reliable or trustworthy
not to be capable of understanding and evaluating the information given to them as part of the formal information policy (informed consent), in particular regarding the risks and discomfort to which they would agree to be exposed
to be in such a precarious financial situation that they no longer weigh up the possible risks of their participation and the unpleasantness they may be involved in
subject is in custody or submitted to an institution due to a judicial